PI3K/AKT/mTOR inhibitors (e.g., everolimus, paxalisib) suppress tumor growth, while epigenetic modulators (EZH2, BET inhibitors) enhance immune recognition (Miklja et al., 2020). Here, EZH2 is linked to neoplasm.